soluble CD40 ligand

Soluble CD40 ligand (sCD40L, also known as CD154 or rhuCD40L) is a recombinant, trimeric form of the human CD40 ligand protein. Originally developed by Immunex (later acquired by Amgen) and subsequently investigated by Celldex Therapeutics, it acts as a potent CD40 agonist. By binding to CD40 receptors on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, it mimics the natural T-cell-dependent costimulatory signal. This interaction upregulates costimulatory molecules (e.g., CD80, CD86, MHC class II) and stimulates the production of proinflammatory cytokines (such as IL-12), thereby licensing dendritic cells to prime tumor-specific CD8+ T cells and promoting antitumor immune responses. It has been clinically evaluated in early-phase trials for advanced solid tumors, non-Hodgkin's lymphoma, and X-linked hyper-IgM syndrome (XHIM).

Brand names

Avrend

Other names

CD154CD-154CD 154CD40 ligandCD-40 ligandCD 40 ligandCD40-LCD-40-LCD 40-LCD40LCD-40LCD 40Lgp39gp-39gp 39recombinant human CD154recombinant human CD40 ligandrecombinant human soluble CD40 ligandsoluble CD154T-BAMTRAP